secwatch.observer — SEC 8-K summary
======================================

Issuer:     GRI Bio, Inc. (GRI)
CIK:        0001824293
Form:       8-K
Filed at:   2026-01-15T23:59:59+00:00
Accession:  0001824293-26-000009
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 5.07, 8.01
LLM model:  deepseek-v4-flash:cloud@v2

GRI Bio shareholders approve reverse stock split; company addresses Nasdaq equity deficiency with $8M offering
--------------------------------------------------------------------------------

- Shareholders approved reverse stock split at ratio between 1:2 and 1:30, with board discretion to set exact ratio or abandon.
- Company received Nasdaq deficiency notice on Nov 26, 2025 for stockholders' equity below $2.5M.
- Dec 12, 2025 public offering raised ~$8.0M gross proceeds, bringing equity above the $2.5M minimum.
- Nasdaq will monitor compliance at next periodic report; failure may lead to delisting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000009/0001824293-26-000009-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1824293/000182429326000009/val-20260115.htm
  HTML page:      https://secwatch.observer/filing/0001824293-26-000009

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer